Envestnet Asset Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.7M | Buy |
271,248
+24,343
| +10% | +$1.36M | ﹤0.01% | 1564 |
|
|
2025
Q4 | $13.8M | Buy |
246,905
+23,039
| +10% | +$1.19M | ﹤0.01% | 1481 |
|
|
2025
Q3 | $10.7M | Buy |
+223,866
| New | +$10M | ﹤0.01% | 1721 |
|
|
2023
Q3 | – | Sell |
-49,963
| Closed | -$2.05M | – | 4175 |
|
|
2023
Q2 | $2.05M | Buy |
49,963
+12,771
| +34% | +$527K | ﹤0.01% | 2258 |
|
|
2023
Q1 | $1.53M | Buy |
37,192
+7,203
| +24% | +$303K | ﹤0.01% | 2373 |
|
|
2022
Q4 | $1.23M | Buy |
29,989
+439
| +1% | +$18.3K | ﹤0.01% | 2487 |
|
|
2022
Q3 | $1.19M | Sell |
29,550
-102,847
| -78% | -$4.4M | ﹤0.01% | 2423 |
|
|
2022
Q2 | $5.56M | Buy |
132,397
+89,553
| +209% | +$3.76M | ﹤0.01% | 1466 |
|
|
2022
Q1 | $1.94M | Buy |
42,844
+665
| +2% | +$29.2K | ﹤0.01% | 2211 |
|
|
2021
Q4 | $1.95M | Buy |
42,179
+2,085
| +5% | +$98.8K | ﹤0.01% | 2200 |
|
|
2021
Q3 | $1.9M | Sell |
40,094
-624
| -2% | -$31K | ﹤0.01% | 2119 |
|
|
2021
Q2 | $2.11M | Sell |
40,718
-2,153
| -5% | -$108K | ﹤0.01% | 2015 |
|
|
2021
Q1 | $2.16M | Buy |
42,871
+652
| +2% | +$34.8K | ﹤0.01% | 1893 |
|
|
2020
Q4 | $2.2M | Sell |
42,219
-546
| -1% | -$26.1K | ﹤0.01% | 1702 |
|
|
2020
Q3 | $1.86M | Sell |
42,765
-1,314
| -3% | -$57.6K | ﹤0.01% | 1648 |
|
|
2020
Q2 | $1.9M | Buy |
44,079
+6,961
| +19% | +$288K | ﹤0.01% | 1605 |
|
|
2020
Q1 | $1.34M | Buy |
37,118
+6,840
| +23% | +$291K | ﹤0.01% | 1645 |
|
|
2019
Q4 | $1.38M | Buy |
+30,278
| New | +$1.2M | ﹤0.01% | 1818 |
|
|
2019
Q2 | – | Sell |
-35,917
| Closed | -$1.49M | – | 3090 |
|
|
2019
Q1 | $1.49M | Buy |
+35,917
| New | +$1.46M | ﹤0.01% | 1633 |
|
|
2018
Q4 | – | Sell |
-35,835
| Closed | -$1.74M | – | 2920 |
|
|
2018
Q3 | $1.74M | Buy |
35,835
+34,921
| +3,821% | +$1.65M | ﹤0.01% | 631 |
|
|
2018
Q2 | $40K | Buy |
914
+41
| +5% | +$1.72K | ﹤0.01% | 2273 |
|
|
2018
Q1 | $35K | Buy |
873
+1
| +0.1% | +$44 | ﹤0.01% | 2244 |
|
|
2017
Q4 | $38K | Sell |
872
-175
| -17% | -$7.44K | ﹤0.01% | 2392 |
|
|
2017
Q3 | $45K | Hold |
1,047
| – | – | ﹤0.01% | 2310 |
|
|
2017
Q2 | $46K | Buy |
1,047
+177
| +20% | +$7.46K | ﹤0.01% | 2383 |
|
|
2017
Q1 | $36K | Hold |
870
| – | – | ﹤0.01% | 2525 |
|
|
2016
Q4 | $34K | Buy |
+870
| New | +$35.4K | ﹤0.01% | 2543 |
|
|
2016
Q3 | – | Sell |
-1,507
| Closed | -$63K | – | 3073 |
|
|
2016
Q2 | $63K | Sell |
1,507
-29
| -2% | -$1.23K | ﹤0.01% | 2631 |
|
|
2016
Q1 | $62K | Sell |
1,536
-224
| -13% | -$9.49K | ﹤0.01% | 2629 |
|
|
2015
Q4 | $90K | Sell |
1,760
-5,478
| -76% | -$279K | ﹤0.01% | 2416 |
|
|
2015
Q3 | $340K | Sell |
7,238
-97,812
| -93% | -$5.89M | ﹤0.01% | 1766 |
|
|
2015
Q2 | $6.55M | Sell |
105,050
-10,376
| -9% | -$646K | 0.03% | 503 |
|
|
2015
Q1 | $7.13M | Buy |
115,426
+43,496
| +60% | +$2.58M | 0.04% | 453 |
|
|
2014
Q4 | $3.88M | Buy |
71,930
+6,478
| +10% | +$354K | 0.04% | 259 |
|
|
2014
Q3 | $3.47M | Sell |
65,452
-786
| -1% | -$40K | 0.03% | 293 |
|
|
2014
Q2 | $3.44M | Buy |
66,238
+40,762
| +160% | +$1.97M | 0.04% | 274 |
|
|
2014
Q1 | $1.19M | Sell |
25,476
-23,272
| -48% | -$1.1M | 0.01% | 415 |
|
|
2013
Q4 | $2.14M | Buy |
48,748
+41,966
| +619% | +$1.75M | 0.02% | 298 |
|
|
2013
Q3 | $261K | Buy |
6,782
+4,850
| +251% | +$183K | ﹤0.01% | 739 |
|
|
2013
Q2 | $68K | Buy |
+1,932
| New | +$65.2K | ﹤0.01% | 1101 |
|
Other funds holding XPH
KWM
FCBT
Envestnet Asset Management's XPH Position: Q1 2026 in Review
Envestnet Asset Management increased its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 9.9% in Q1 2026, buying an estimated $1.36M and bringing the position to 271,248 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1564.
Envestnet Asset Management first reported a position in XPH in Q2 2013 and has held it in 40 quarters since. 82 funds tracked by Wall St. Rank hold XPH as of Q1 2026.
- Envestnet Asset Management held 271,248 shares of State Street SPDR S&P Pharmaceuticals ETF worth $14.7M as of Q1 2026.
- Envestnet Asset Management bought 24,343 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2026, an estimated $1.36M.
- State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Envestnet Asset Management's portfolio in Q1 2026, its #1564 holding.
- Envestnet Asset Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2013 and has held it in 40 quarters since.
- 82 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2026.
Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.